A randomized, single-blind, multicenter study was conducted to evaluate the safety and efficacy of cefuroxime axetil and cefadroxil suspensions for the treatment of skin or skin structure infections in 287 children. Each drug was given at a dosage of 30 mg/kg of body weight per day in two divided doses. Staphylococcus aureus and Streptococcus pyogenes, or a combination of the two, were the primary pathogens isolated from infected skin lesions. A satisfactory bacteriological response (cure or presumed cure) was obtained in 97.1 and 94.3% of children in the cefuroxime axetil and cefadroxil groups, respectively (P > 0.05). Satisfactory clinical responses (cure or improvement) were more likely to occur in cefuroxime axetil recipients than in cefadroxil recipients (97.8 versus 90.3%; P < 0.05). Both regimens were equally well tolerated, with adverse events occurring in 7.9 and 6.1% of cefuroxime axetil and cefadroxil recipients, respectively. There were more patients who refused to take cefuroxime axetil (7 of 189) than there were who refused to take cefadroxil (0 of 98), but the difference was not statistically significant (P = 0.1). In this study, cefuroxime axetil was at least as effective as cefadroxil in resolving skin and skin structure infections in children.
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Cefuroxime is an expanded-spectrum cephalosporin with improved P-lactamase stability and a broad spectrum of activity against clinically important gram-positive and gramnegative pathogens. The lowest concentrations that inhibited the growth of 90% of the Staphylococcus aureus and Streptococcus pyogenes strains tested are 1 to 2 and <0. 125 ,ug/ml, respectively (2) .
Cefuroxime axetil, the acetyloxyethyl ester of cefuroxime, is a prodrug that is suitable for oral administration. After oral ingestion, cefuroxime axetil is deesterified in the intestinal mucosa and appears as cefuroxime in the blood. Peak concentrations in serum increase in proportion to dose and are 3.3 and 5.1 ,ug/ml after oral doses of a cefuroxime axetil suspension of 10 and 15 mg/kg of body weight, respectively (12) . These results are comparable to those achieved in adults following administration of a 250-mg cefuroxime axetil tablet (7) . Thus, achievable concentrations in serum exceed the MICs for common cutaneous pathogens (2) . The tablet formulation of cefuroxime axetil has previously been found to be effective in the treatment of skin or skin structure infections in adults (4, 5) .
The purpose of the study described here was to evaluate the efficacy and safety of a new liquid suspension of cefuroxime axetil in children with skin or skin structure infections. Cefadroxil suspension was selected as the active control because it has been proven to be effective in the treatment of skin or skin structure infections and is suitable for twice-daily administration. Other diagnoses were furunculosis (for the cefuroxime axetil and cefadroxil treatment groups, 2 and 0 patients, respectively), pyoderma (1 and 3 patients, respectively), carbunculosis (1 and 0 patients, respectively), buttock abscess (1 and 0 patients, respectively), folliculitis (1 and 0 patients, respectively), skin infection began as contact dermatitis (1 and 0 patients, respectively), lymphangitis (0 and 1 patient, respectively), and nonspecific skin rash with exudates (0 and 1 patient, respectively).
collected for complete blood count with differential, platelet count, prothrombin time, and the direct Coomb's test and for evaluation of hepatic enzymes, blood urea nitrogen, and serum creatinine. Urine was obtained for evaluation of albumin and glucose and a microscopic examination. These tests were performed at the initial and posttreatment visits.
Statistical analysis. Two-sided statistical tests were used. Demographic data were summarized by using a van Elteren statistic (13) (8 and 1 patient, respectively) , absence of susceptibility testing on pretreatment pathogen (6 and 4 patients, respectively), resistant pathogen (2 and 0 patients, respectively), and concurrent antimicrobial therapy (0 and 1 patient, respectively). The two resistant pathogens were methicillin-resistant S. aureus. One cefuroxime axetiltreated patient from whom no pathogen was isolated in the pretreatment culture was withdrawn from the study because of the patient's refusal to take the study medication. Two additional patients who were withdrawn from the study because of refusal to take the study medication were excluded from the analysis because of prior negative urine bioassays. The remaining six patients with negative urine bioassays were either lost to follow-up (n = 3) or completed the study but did not return medication bottles to provide other evidence of compliance (n = 3). The cefadroxil-treated patient completed the study but did not return medication bottles to provide other evidence of compliance. In total, three cefuroxime axetil-treated patients who refused to take the study medication were excluded from analysis because of the prespecified protocol violations described above; data for these patients are not given below in the bacteriological and clinical outcome sections. All patients with protocol violations were included in an intent-to-treat analysis, the results of which appear later in this report. There were no differences (P > 0.05) between the two treatment groups in the proportion of patients with any particular reason for exclusion from analysis.
After excluding the 49 patients, 156 patients in the cefuroxime axetil treatment group and 82 patients in the cefadroxil treatment group were available for bacteriological and clinical efficacy analyses. These remaining patients were evenly distributed on the basis of age, weight, and sex but not ethnic origin. The majority of cefadroxil recipients were Caucasian, whereas cefuroxime axetil recipients were nearly evenly divided between Caucasian and black ethnic origins (P < 0.007). The primary diagnosis in both groups was impetigo; this was followed in descending order of frequency by cellulitis, injury-induced wound infection, and paronychia. The mean dose received (approximately 28 mg/kg/day) and the duration of treatment (10 days) (Table 2) . Of the seven cefuroxime axetil-treated patients classified by the investigator as receiving less than 5 days of study drug, four withdrew from the study because of refusal to take the study medication, one withdrew before any doses were given, and two withdrew because of an inability to complete the study requirements for personal reasons. Of the cefadroxil-treated patients who received less than 5 days of study drug, one withdrew for personal reasons and cefadroxil recipients, respectively (P = 0.242). In the cefuroxime axetil group, all unsatisfactory responses were associated with infections caused by S. aureus (three failures, one relapse). Likewise, unsatisfactory responses in the cefadroxil group were associated with infections caused by S. aureus (four treatment failures). Two of these patients had polymicrobial infections that were also caused by S. pyogenes or non-group A, ,3-hemolytic streptococci.
When all patients were included in an intent-to-treat analysis (i.e., patients previously excluded because of prespecified protocol violations and patients classified as bacteriologically unevaluable), a satisfactory response was defined as cure or improvement, and an unsatisfactory response was all other responses (including unevaluable). In these evaluable patients, satisfactory responses occurred in 70.9 and 68.4% of cefuroxime axetil and cefadroxil recipients, respectively (P = 0.625) ( Table 3) .
Clinical outcome. Twenty-eight patients were clinically unevaluable because of failure to return for follow-up, drug treatment for less than 5 days (less than 10 doses), or withdrawal from the study for reasons other than an adverse event (Table 4) . Six cefuroxime axetil recipients were classified by the investigator as receiving drug for less than 5 days. These patients were described above in the bacterio- logical outcome section. In addition, the one patient who was unevaluable because of reasons other than an adverse event was the patient who was withdrawn from the study prior to receiving any study drug (classified as receiving drug for less than 5 days in the bacteriological outcome assessment). No cefadroxil-treated patients were classified as clinically unevaluable by the investigator because they had received study drug for less than 5 days. The two patients in this category under bacteriological outcome were considered clinical failures because of an adverse event or were withdrawn from the study for reasons other than an adverse event (i.e., personal reasons). For the remaining patients, satisfactory clinical response rates were higher in cefuroxime axetil than in cefadroxil recipients (97.8 versus 90.3%; P = 0.009). When the patients that were excluded from the "clinical outcome" analysis were reassessed as having unsatisfactory outcomes, i.e., an intent-to-treat analysis, the difference in response rates in favor of cefuroxime axetil (81.5 versus 78.6%) was no longer statistically significant (P = 0.5) ( Table  5 ). This can be explained by the addition of more patients who were previously excluded from the cefuroxime axetil group because of poor compliance. However, 86.7 and 88.8% of cefuroxime axetil and cefadroxil recipients, respectively, completed at least 80% of the prescribed therapies. Adverse events. In general, adverse events were mild to moderate in severity. One patient discontinued cefuroxime axetil because of diarrhea, which resolved spontaneously without further treatment. One patient discontinued cefadroxil because of a rash, which resolved spontaneously. Adverse events considered by the clinician to be possibly, probably, or almost certainly related to the study drugs occurred in 7.9 and 6.1% of all cefuroxime axetil and cefadroxil recipients, respectively (P = 0.641) ( Table 6 ). The adverse event profiles were similar in both treatment groups and consisted primarily of gastrointestinal disturbances (e.g., diarrhea or loose stools) and diaper rash. Only one patient, a cefuroxime axetil recipient, experienced an abnormal laboratory value, which consisted of an increase in serum glutamic oxalacetic transaminase from 30 U/liter at the initial visit to 48 U/liter at the posttreatment visit and to 52 U/liter 2 weeks later. The patient remained asymptomatic throughout this period of time. The patient's mother refused further testing, and the physician observer thought that the abnormality could be drug related. Otherwise, there were no clinically significant changes in hematologic or chemistry parameters.
Drug stop dates showed that study drug was taken for 10 days or more by 153 (81.0%) and 84 (85.7%) of cefuroxime axetil and cefadroxil recipients, respectively. One of the study medications was taken for 8 to 9 days by 11 (5.8%) cefuroxime axetil recipients and 3 (3.1%) cefadroxil recipients. Nine (4.7%) cefuroxime axetil-treated patients and two (2.0%) cefadroxil-treated patients took drug for less than 8 days. Of the nine cefuroxime axetil-treated patients who took drug for less than 8 days, six withdrew from the study because of refusal to take the study medication. In addition, one cefuroxime axetil-treated patient was withdrawn from the study because of refusal to take the study medication, but the drug stop date was not recorded. In total, seven (3.7%) cefuroxime axetil-treated patients were withdrawn for this reason. The disposition of these patients for analysis was discussed above. No cefadroxil-treated patients withdrew from the study because of refusal to take the study drug. Drug stop dates were not available for 33 patients (16 cefuroxime axetil recipients, 9 cefadroxil recipients), of which 14 (7.4%) cefuroxime axetil recipients and 7 (7.1%) cefadroxil recipients were lost to follow-up. Of the remaining patients, none were withdrawn because of refusal to take study medication. DISCUSSION This is the first comparative study of a new formulation of cefuroxime axetil suitable for oral administration to children with skin or skin structure infections. Clinical (97.1%) and bacteriological (97.8%) response rates in the current study approximated those reported in adults receiving the tablet formulation. The overall clinical improvement rate was 95% in 97 patients who participated in a noncomparative study (5) . In a study with a design similar to that of the study described here, cefuroxime axetil in the tablet formulation produced clinical and bacteriological response rates (97 and 96%, respectively) higher than those of cephalexin (89 and 85%, respectively; P < 0.05) and similar to those of cefadroxil (94 and 93%, respectively; P > 0.05) (4) . In other comparative studies, the authors concluded that cefuroxime axetil is as effective as amoxicillin-clavulanate (14) and cefaclor (11) . In those trials, clinical and bacteriological response rates from 92 to 97% were achieved.
In the study described here, bacteriological response rates were comparable to those achieved with the cefadroxil suspension (approximately 97% in each group), but clinical responses were higher in cefuroxime axetil recipients (97.8 versus 90.3%; P = 0.009). The difference between treatment groups did not appear to be due to a spuriously low response rate in the cefadroxil group, because the response rate was consistent with those previously reported in comparative trials of patients with skin or skin structure infections (1, 6) .
The new cefuroxime axetil suspension was well tolerated in the study described here. The incidence and profile of adverse events of the cefuroxime axetil suspension closely resembled that of the cefadroxil suspension. Only 7.9% of children experienced adverse events during cefuroxime axetil therapy; these adverse events were primarily manifested as gastrointestinal disturbances (e.g., diarrhea or loose stools) or diaper rash. No episodes of nausea or vomiting were reported in the cefuroxime group.
In this single-blind, randomized study, a suspension formulation of cefuroxime axetil produced bacteriological response rates comparable to those of the cefadroxil suspension (97.1 versus 94.3%) in children with skin or skin structure infections. The clinical response rate was higher in the cefuroxime axetil group (97.8 versus 90.3%; P < 0.05).
Both regimens were well tolerated. These results indicate that the cefuroxime axetil suspension is safe and efficacious in the treatment of skin and skin structure infections in children.
